NTRB

Nutriband, Inc. · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website nutriband.com
Employees(FY) -
ISIN US67092M2089

Performance

-0.49%

-16.9%

-27.14%

-21.39%

+75.86%

YTD

+63.2%

Profile

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Advanced Technical Analysis

Technical Analysis of NTRB 2024-12-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 3 indicating strong downward momentum, an Oscillators Score of 43 suggesting a neutral stance, and a Technical Score of 23 reinforcing the bearish outlook. This combination signals caution for potential investors, as the prevailing trend appears to be negative.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of NTRB

Stock Rank

Recent News & Updates

2024-12-03 20:00
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025(Globenewswire)
2024-12-03 18:00
Nutriband Inc. to Present at The 2024 Noble Conference in Boca Raton on December 4th(Globenewswire)
2024-11-26 18:00
Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa Abuse Deterrent Transdermal Technology(Globenewswire)
2024-10-30 20:35
Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application(Accesswire)
2024-10-16 19:00
Nutriband Inc Mosquito Repellent Patch Approved by Ministry of Health of Costa Rica(Accesswire)
2024-10-01 19:00
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on October 17(Accesswire)
2024-09-23 20:45
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse(Globenewswire)
2024-09-23 19:00
Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology(Accesswire)
2024-09-19 18:50
Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl Transdermal Patch(Accesswire)
2024-09-16 04:00
Nutriband Inc. Authorizes $1M Share Buyback Program(Accesswire)
2024-09-03 19:00
Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025(Accesswire)
2024-07-18 19:00
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on July 25(Accesswire)
2024-07-14 19:00
Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology(Accesswire)
2024-06-24 18:52
NTRB Stock Earnings: Nutriband Reported Results for Q1 2024(Investorplace)
2024-06-19 19:00
Nutriband Provides Product Development Update for Its Lead Product Aversa Fentanyl(Accesswire)
2024-06-02 19:00
Nutriband Inc. Quarterly Report Emphasizes Focus on Kinesiology Tape Output as Q1 Sports Tape Revenues Increase 219% Year Over Year(Accesswire)
2024-05-20 19:00
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on May 30(Accesswire)
2024-05-15 19:00
Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors(Accesswire)
2024-05-09 21:00
Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV(Accesswire)
2024-05-02 23:54
NTRB Stock Earnings: Nutriband Reported Results for Q4 2023(Investorplace)
2024-04-24 19:00
IBN Coverage Initiated for Nutriband Inc.(Globenewswire)
2024-04-23 19:00
Nutriband Closes $8.4M Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission(Accesswire)
2024-04-23 19:00
Nutriband Closes $8.4M Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission(Accesswire)
2024-04-22 19:00
Nutriband Inc. Signs Exclusive Supplier Agreement with Major Sports Brand Licensee Fit for Life Group(Accesswire)
2024-04-18 19:00
Nutriband Inc. Announces $8.4M Private Placement(Accesswire)
2024-03-31 19:00
Nutriband Inc. Begins Manufacturing for Major Sports Brand Licensee Fit for Life Group, Whose Collection of Partnered Brands Include Reebok, Adidas and New Balance(Accesswire)
2024-03-26 17:50
Nutriband Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal Patch(Accesswire)
2024-03-24 19:00
Nutriband Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented at 2024 American Academy of Pain Medicine Annual Meeting(Accesswire)
2024-03-03 18:00
Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annual Meeting(Accesswire)
2024-01-28 18:00
Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st(Accesswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.